Literature DB >> 3872664

Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases.

T R Dykman, O S Gluck, W A Murphy, T J Hahn, B H Hahn.   

Abstract

In 161 ambulatory rheumatic disease patients receiving long-term prednisone therapy, diaphyseal mass (DM) and metaphyseal mass (MM) of the forearm were measured by single photon absorptiometry, and bone radiographs were reviewed when available. Multivariate analysis of treatment and patient characteristics demonstrated that glucocorticoid-induced osteopenia (defined as an elevated DM:MM ratio) and bone fractures occurred with similar frequency in patients of each sex, in whites and blacks, in patients with various rheumatic diseases, and in patients receiving different regimens of prednisone therapy. However, large cumulative doses of prednisone were associated with elevated DM:MM ratios as well as with bone fractures, and menopause or age greater than or equal to 50 years (males or females) was associated with bone fractures. We conclude that long-term therapy with various prednisone regimens results in glucocorticoid-induced osteopenia and fractures. This affect is cumulative, occurs in all patient groups, and results in more bone fractures in certain groups.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872664     DOI: 10.1002/art.1780280402

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

1.  Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors:  W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

2.  Steroid induced osteoporosis.

Authors:  W F Lems; J W Bijlsma
Journal:  BMJ       Date:  1992-11-28

Review 3.  Management of corticosteroid-induced osteoporosis: a clinician's perspective.

Authors:  S L Silverman
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 4.  Bone mass in patients with rheumatoid arthritis.

Authors:  R F Laan; P L van Riel; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 5.  Adverse neurologic effects of glucocorticosteroids.

Authors:  D Lacomis; M A Samuels
Journal:  J Gen Intern Med       Date:  1991 Jul-Aug       Impact factor: 5.128

6.  Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.

Authors:  A Balasubramanian; S W Wade; R A Adler; C J F Lin; M Maricic; C D O'Malley; K Saag; J R Curtis
Journal:  Osteoporos Int       Date:  2016-06-08       Impact factor: 4.507

Review 7.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  F Eggelmeijer
Journal:  Pharm World Sci       Date:  1998-10

8.  Prevention of glucocorticoid induced osteoporosis.

Authors:  J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

9.  Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.

Authors:  A J Taggart; C Astbury; J S Dixon; H A Bird
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

10.  Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.

Authors:  R Roubenoff; R A Roubenoff; J G Cannon; J J Kehayias; H Zhuang; B Dawson-Hughes; C A Dinarello; I H Rosenberg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.